Annexon CEO Touts “Win Year” 2026 at Needham, Eyes GA Phase III Data and GBS FDA Filing [Yahoo! Finance]
Annexon, Inc. - common stock (ANNX)
Company Research
Source: Yahoo! Finance
the 25th Annual Needham Healthcare Conference, describing 2026 as a “win year” after more than a decade of work developing therapies that target the classical complement pathway. Key milestones highlighted for 2026 Love said the company expects multiple catalysts across its pipeline over the course of the year, led by programs in Guillain-Barré syndrome (GBS), geographic atrophy (GA), and an oral small-molecule candidate. GBS: Love said Annexon has filed for regulatory approval in Europe following a “very successful phase III pivotal study” and anticipates an approval decision in the “first part of 2027.” He added that the company anticipates filing for U.S. approval with the FDA “later this year,” describing submission of the BLA as a key milestone. ANX1502: Love said the company expects a proof-of-concept readout this year for ANX1502, which he described as “the first small molecule targeting the classical pathway.” Geographic atrophy: Love said the company's phase III pro
Show less
Read more
Impact Snapshot
Event Time:
ANNX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANNX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANNX alerts
High impacting Annexon, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
ANNX
News
- Annexon to Present at the 25th Annual Needham Virtual Healthcare ConferenceGlobeNewswire
- Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans? [Yahoo! Finance]Yahoo! Finance
- Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated MilestonesGlobeNewswire
- Annexon (ANNX) had its "buy" rating reaffirmed by Chardan Capital. They now have a $16.00 price target on the stock.MarketBeat
- Annexon Investor Day: ANX007 Targets C1q in Dry AMD GA as Phase III Readout Nears Q4 [Yahoo! Finance]Yahoo! Finance
ANNX
Earnings
- 3/30/26 - Beat
ANNX
Sec Filings
- 4/16/26 - Form PRE
- 4/14/26 - Form 4
- 3/31/26 - Form S-8
- ANNX's page on the SEC website